Skip to main content Accessibility help
×
Home

Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting

  • T Harris (a1), S Peer (a2) and J J Fagan (a2)

Abstract

Ototoxic drugs are widely used in the developing world, without audiological monitoring. Epidemiological data on ototoxic deafness are lacking for developing countries. The public health aspect of ototoxicity is often overlooked, to the detriment of the individual patient. This paper reviews ototoxic hearing loss, particularly in sub-Saharan Africa, and also assesses the impact of treatments for tuberculosis, cancer and human immunodeficiency virus (the latter including highly active antiretroviral therapy) on ototoxic hearing loss. The paper also discusses obstacles to audiological monitoring for ototoxicity in the developing world, and the potential of audiology screening using applications for mobile devices.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting
      Available formats
      ×

Copyright

Corresponding author

Address for correspondence: Dr Tasneem Harris, Division of Otorhinolaryngology, University of Cape Town, H-53 OMB, Groote Schuur Hospital, Observatory, Cape Town 7925, South Africa Fax: +27 21 448 8865 E-mail: harristasneem@yahoo.com

References

Hide All
1Olusanya, BO, Newton, VE. Promoting a global health agenda for permanent childhood hearing impairment. Journal of Community Ear and Hearing Health 2007;4:527
2World Health Organization. Report of an Informal Consultation on Strategies for Prevention of Hearing Impairment from Ototoxic Drugs. Geneva: World Health Organization, 1994
4Birchall, MA, Wight, RG, French, PD, Cockbain, Z, Smith, SJ. Auditory function in patients infected with the human immunodeficiency virus. Clin Otolaryngol 1992;17:117–21
5Lalwani, AK, Sooy, CD. Otologic and neurotologic manifestations of acquired immunodeficiency syndrome. Otolaryngol Clin North Am 1992;25:1183–97
6Soucek, S, Michaels, L. The ear in the acquired immunodeficiency syndrome: II. Clinical and audiologic investigation. Am J Otol 1996;17:35–9
7Fagan, JJ, Jacobs, M. Survey of ENT services in Africa: need for a comprehensive intervention. Global Health Action 2009;Mar 19:2
8Saunders, JE, Greinwald, JH, Vaz, S, Guo, Y. Aminoglycoside ototoxicity in Nicaraguan children: patient risk factors and mitochondrial DNA results. Otolaryngol Head Neck Surg 2009;140:103–7
9World Health Organization. Global Tuberculosis Control 2008: Surveillance, Planning, Financing. Geneva: WHO Report, 2008
10World Health Organization. Multidrug and extensively drug resistant TB (M/XDR-TB). 2010 Report on Surveillance and Response. Geneva: World Health Organization, 2010
11Rybak, LP, Whitworth, CA. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005;10:1313–21
12Bokemeyer, C, Berger, CC, Hartmann, JT, Kollmansberger, C, Schmoll, HJ, Kuczyck, MA et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 1998;77:1355–62
13Rybak, LP, Whitworth, CA, Mukherjea, D, Ramkumar, V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2006;226:157–67
14Huang, E, Teh, BS, Strother, DR, Davis, QG, Chiu, JK, Lu, HH. Intensity-modulated radiation therapy for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys 2002;52:599605
15Chandrasekhar, SS, Connelly, PE, Brahmbhatt, SS, Shah, CS, Kloser, PC, Baredes, S. Otologic and audiologic evaluation of human immunodeficiency virus-infected patients. Am J Otolaryngol 2000;21:19
16Michaels, L, Soucek, S, Liang, J. The ear in the acquired immunodeficiency syndrome: I. Temporal bone histopathologic study. Am J Otol 1994;15:515–22
17Meynard, JL, el Amrani, M, Meyohas, MC, Fligny, I, Gozian, J, Rozenbaum, W et al. Two cases of cytomegalovirus infection revealed by hearing loss in HIV-infected patients. Biomed Pharmacother 1997;51:461–3
18Little, JP, Gardner, G, Acker, JD, Land, MA. Otosyphilis in a patient with human immunodeficiency virus: internal auditory canal gumma. Otolaryngol Head Neck Surg 1995;112:488–92
19Grimaldi, LME, Luzi, L, Martino, GV, Furlan, R, Nemni, A, Antonelli, N et al. Bilateral eighth cranial nerve neuropathy in human immuodeficiency virus infection. J Neurol 1993;240:363–6
20McArthur, JC. Neurological manifestations of AIDS. Medicine 1987;66:407–37
21Moore, JM, James, IR, Nolan, D, Upton, RP, McKinnon, EJ, Mallal, SA. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717–23
22Brinkman, K, Smeitink, JA, Romijn, JA, Reiss, P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112–15
23Anuurad, E, Semrad, A, Berglund, L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009;7:401–9
24Marra, CM, Wechkin, HA, Longstreth, WT, Rees, T, Syapin, CL, Gates, GA. Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch Neurol 1997;54:407–10
25Simdon, J, Watters, D, Bartlett, S, Connick, E. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis 2001;32:1623–7
26McNaghten, AD, Wan, PT, Dworkin, MS. Correspondence: prevalence of hearing loss in a cohort of HIV-infected patients. Arch Otolaryngol Head Neck Surg 2001;127:1516–18
27Khoza-Shangase, K. Highly active antiretroviral therapy: does it sound toxic? J Pharm Bioallied Sci 2011;3:142–53
28Bektas, D, Martin, GK, Stagner, BB, Lonsbury-Martin, BL. Noise-induced hearing loss in mice treated with antiretroviral drugs. Hear Res 2008;239:6978
29Silverberg, MJ, Chao, C, Leyden, WA, Xu, L, Horberg, MA, Klein, D et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol Biomarkers Prev 2011;20:2551–9
30Fausti, SA, Helt, WJ, Gordon, JS, Reavis, KM, Phillips, DS, Konrad-Martin, D. Audiologic monitoring for ototoxicity and patient management. In: Campbell, KC, ed. Pharmacology and Ototoxicity for Audiologists, 1st edn.New York: Thomson Delmar Learning, 2006;230–48
31Sturdy, A, Goodman, A, José, RJ, Loyse, A, O'Donoghue, M, Kon, OM et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother 2011;66:1815–20
32Swart, S. Draft Report. Modernisation of Audiology Services. Cape Town: Western Cape Department of Health, 2010
33DOTS-Plus for Standardised Management of Multidrug-resistant Tuberculosis in South Africa – Policy Guidelines. In: http://www.sahealthinfo.org/tb/mdrtbguidelines.pdf [17 November 2011]

Keywords

Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting

  • T Harris (a1), S Peer (a2) and J J Fagan (a2)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed